XOMA Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Rezolute - Second Amendment (Details)

Licensing and Other Arrangements - Rezolute - Second Amendment (Details) $ in Thousands				1 Months Ended				2 Months Ended	3 Months Ended			10 Months Ended	12 Months Ended				13 Months Ended
	Jan. 30, 2019 USD ($)	Jan. 07, 2019 USD ($) payment	Apr. 03, 2018 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Apr. 30, 2018 USD ($)	Mar. 31, 2018 USD ($) item	Aug. 31, 2019 USD ($) item	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2020 shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)
Licensing and other arrangements
Revenue from contracts with customers														$ 17,276		$ 5,068
Rezolute \| License Agreement and Common Stock Purchase Agreement
Licensing and other arrangements
Amount of Rezolute's common stock eligible to receive		$ 8,500					$ 8,500										$ 8,500
Number of future cash payments upon closing of the qualified financing \| payment		5
Future cash payments upon closing of the qualified financing		$ 8,500
Percentage of net proceeds of each future financing upon closing of the qualified financing		15.00%
Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange \| shares														5,000,000
Gross proceeds received by third party from preferred stock financing	$ 25,000
Consideration received following qualified financing event	5,500													$ 5,500
Reimbursable technology transfer expense received	$ 300		$ 300
Amount of future cash payments from counterparty company may receive					$ 8,500
Revenue from contracts with customers					2,500					$ 6,000	$ 1,800			14,000		1,800
Doubtful revenue reversal of future cash payments					$ 2,500			$ 3,600									$ 2,500
Number of common stock financing events \| item								2
Early payment of unrecognized future cash payments								$ 3,400
Unrecognized future cash payments				$ 6,000
Future cash payments received								$ 1,500	$ 1,000	$ 4,900
Number of performance obligations \| item							1
Outstanding receivable									2,600					2,600	$ 2,600
Future cash payments of revenue recognized														8,500
Contract assets									0			$ 0		0	0	0
Contract liabilities									0			0		0	0	0
Capitalized contract costs									$ 0			$ 0		$ 0	$ 0	$ 0
Rezolute \| License Agreement and Common Stock Purchase Agreement \| Maximum
Licensing and other arrangements
Future cash payments upon closing of the qualified financing		$ 8,500
Rezolute \| License Agreement
Licensing and other arrangements
Reimbursable technology transfer expense received						$ 300
Rezolute \| Common Stock Purchase Agreement
Licensing and other arrangements
Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange \| shares												5,000,000			5,000,000
Rezolute \| Common Stock Purchase Agreement \| Forecast
Licensing and other arrangements
Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange \| shares													2,500,000